Poland· PL-100315723
Vimizim
A elosulfase alfa product containing elosulfasum alfa, registered in Poland by BioMarin International Ltd.. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Elosulfase alfa is registered in 14 of 19 countries.
Countries holding a registration under ATC A16AB12 (elosulfase alfa), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Elosulfase alfa · ATC A16AB12
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Elosulfasum alfa
- Manufacturer
- BioMarin International Ltd.
- Country
- Poland (PL)
- ATC code
- A16AB12
- ATC class
- Elosulfase alfa
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05909991137632
- gtin05391524461978
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Elosulfase alfa in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayVimizimOrifarm AS
- SwitzerlandVimizim 5mg/5ml, Konzentrat zur Herstellung einer InfusionslösungDRAC AG
- CzechiaVIMIZIMBioMarin International Limited, Dublin
- FinlandVimizimBiomarin International Limited
- IrelandVimizim 1 mg/ml concentrate for solution for infusionBiomarin International Limited
- IcelandVimizimBioMarin International Limited
- SwedenVimizim 1 mg/ml Koncentrat till infusionsvätska, lösningBioMarin International Limited
- BelgiumVimizim 1 mg/mlBioMarin International
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Vimizim
- Liechtenstein · Vimizim
- Norway · Vimizim
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/63244d68-17f3-40f8-b281-16b139e2666e GET /v1/drugs/63244d68-17f3-40f8-b281-16b139e2666e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "1 mg/ml",
"packaging": "05909991137632 ¦ Rpz ¦ EU/1/14/914/001 ¦ 91310\n1 fiol. 5 ml\n¦ UR/Z/4c/202/26 - 05391524461978",
"substance": "Elosulfasum alfa 1 mg/ml",
"common_name": "Elosulfasum alfa",
"pl_product_id": "100315723",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about elosulfase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.